LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00

LifeStance Health Group (NASDAQ:LFST) had its target price upped by equities research analysts at KeyCorp from $8.00 to $9.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 26.85% from the stock’s previous close.

A number of other research analysts have also weighed in on the stock. BTIG Research raised their price target on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. Barclays assumed coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price on the stock. Finally, BMO Capital Markets began coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.00.

LifeStance Health Group Stock Down 4.3%

Shares of NASDAQ:LFST traded down $0.32 during mid-day trading on Thursday, hitting $7.10. 2,944,276 shares of the company traded hands, compared to its average volume of 1,795,452. The stock has a 50-day moving average price of $7.12 and a two-hundred day moving average price of $6.18. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The stock has a market cap of $2.76 billion, a P/E ratio of -233.37 and a beta of 1.12. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.02). The company had revenue of $382.20 million for the quarter, compared to the consensus estimate of $378.51 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. LifeStance Health Group’s revenue was up 17.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.01) earnings per share. On average, equities research analysts forecast that LifeStance Health Group will post -0.18 earnings per share for the current year.

LifeStance Health Group declared that its Board of Directors has authorized a share repurchase program on Wednesday, February 25th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to buy up to 3.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director directly owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ann Varanakis sold 50,000 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the sale, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. The trade was a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 270,086 shares of company stock worth $1,891,264 over the last 90 days. 3.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently modified their holdings of LFST. Royal Bank of Canada grew its stake in LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after acquiring an additional 27,244 shares in the last quarter. AQR Capital Management LLC boosted its holdings in LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock valued at $343,000 after purchasing an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in LifeStance Health Group by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after purchasing an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of LifeStance Health Group by 1.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after purchasing an additional 11,331 shares in the last quarter. Finally, Corton Capital Inc. grew its position in shares of LifeStance Health Group by 97.7% during the 2nd quarter. Corton Capital Inc. now owns 26,655 shares of the company’s stock valued at $138,000 after purchasing an additional 13,171 shares in the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 revenue and profitability improved materially — revenue rose 17% to $382.2M, full‑year revenue grew 14%, Q4 net income was $11.7M and adjusted EBITDA jumped 49%, signalling stronger demand and operating leverage. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Board approved a $100M share repurchase program (up to ~3.6% of outstanding shares), which supports buyback-driven capital return and signals management confidence. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Company provided 2026 guidance: revenue $1.615B–$1.655B and adjusted EBITDA $185M–$205M. Guidance is growth‑oriented but investors will monitor execution vs. the midpoint. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Some outlets emphasize that revenue and other metrics beat estimates (revenue beat consensus), while EPS coverage is mixed depending on the comparator — this creates divergent analyst/tone impact. LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
• Negative Sentiment: Reported EPS of $0.03 missed the consensus ~$0.05 (market‑reported miss), which likely disappointed short‑term earnings expectations despite revenue strength. LifeStance Health Group, Inc. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company not selling/receiving proceeds), creating immediate supply overhang and downward pressure on the float. LifeStance Health Group Announces Launch of Secondary Public Offering
• Negative Sentiment: Recent insider selling and some large institutional reductions noted in public data, which can amplify selling pressure and investor caution. QuiverQuant summary of Q4 results and insider activity

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.